Literature DB >> 10980987

Evolutionary biologic therapy for inflammatory bowel disease.

S B Hanauer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10980987     DOI： 10.1007/s11894-999-0004-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


× No keyword cloud information.
  10 in total

Review 1.  Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Authors:  W J Sandborn; S B Hanauer
Journal:  Inflamm Bowel Dis       Date:  1999-05       Impact factor: 5.325

2.  Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors:  D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal:  N Engl J Med       Date:  1999-05-06       Impact factor: 91.245

3.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

Review 4.  Inflammatory bowel disease: etiology and pathogenesis.

Authors:  C Fiocchi
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

Review 5.  Tumour necrosis factor and Crohn's disease.

Authors:  S J Van Deventer
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 6.  Management of Crohn's disease in adults.

Authors:  S B Hanauer; S Meyers
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

7.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Authors:  P Rutgeerts; G D'Haens; S Targan; E Vasiliauskas; S B Hanauer; D H Present; L Mayer; R A Van Hogezand; T Braakman; K L DeWoody; T F Schaible; S J Van Deventer
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

Review 8.  Advances in the management of Crohn's disease: economic and clinical potential of infliximab.

Authors:  S B Hanauer; R D Cohen; R V Becker; L R Larson; M G Vreeland
Journal:  Clin Ther       Date:  1998 Sep-Oct       Impact factor: 3.393

9.  Biologic therapy for inflammatory bowel disease.

Authors:  B E Sands
Journal:  Inflamm Bowel Dis       Date:  1997       Impact factor: 5.325

10.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

Authors:  H M van Dullemen; S J van Deventer; D W Hommes; H A Bijl; J Jansen; G N Tytgat; J Woody
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.